DGAP-News: Interim Report for the 6 months ended June 30, 2011

Genmab A/S

03.08.2011 17:31
—————————————————————————

– Continued strong focus on cost control with improvement in first half
operating loss and cash burn over 2010
– Improving 2011 guidance as result of DKK 25 million reduction in operating
expenses
– Announced HuMax-CD74(TM) antibody-drug conjugate program with Seattle Genetics
– Decisive move to minimize future spending by winding down the zalutumumab
program

In order to read Genmab–s Interim Report for the 6 months ended June 30, 2011
please see the attached file.

Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations&Communication
T: +45 33 44 77 20
M: +45 25 12 62 60
E: r.gravesen@genmab.com
www.genmab.com

Company Announcement no. 24
CVR no. 2102 3884

Genmab A/S
Bredgade 34
1260 Copenhagen K
Denmark

03.08.2011 Dissemination of a Corporate News, transmitted by DGAP –
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

DGAP–s Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

—————————————————————————

Language: English
Company: Genmab A/S

Denmark
Phone:
Fax:
E-mail:
Internet:
ISIN: DK0010272202
WKN:

End of Announcement DGAP News-Service

—————————————————————————